Magdalena E Sobieszczyk, MD, MPH

Infectious Disease
Profile Headshot

Profile Navigation

Overview

Dr. Magdalena Sobieszczyk is the Harold Neu Professor of Infectious Diseases (in Medicine) at the Columbia University Medical Center. She is the Chief of Infectious Diseases at the Columbia University Irving Medical Center in New York. Dr. Sobieszczyk is a clinical virologist and the principal investigator of the NIH-funded Columbia Collaborative Clinical Trials Unit which has been advancing the science of HIV and emerging infections like SARS-CoV-2.

Areas of Expertise / Conditions Treated

  • HIV (Human Immunodeficiency Virus Infection)
  • HIV/AIDS
  • HIV Medicine

Academic Appointments

  • Harold C. Neu Professor of Infectious Diseases (in Medicine) at the Columbia University Medical Center

Administrative Titles

  • Associate Fellowship Program Director
  • Chief, Division of Infectious Diseases

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Allen Hospital

Gender

  • Female

Schedule an Appointment

Phone Appointments

New and Existing Patients:
(212) 305-8039

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

CUIMC/Harkness Pavilion
180 Fort Washington Avenue
Suite 2-242
New York, NY 10032
Primary
Phone:
(212) 305-8039
Fax:
(212) 305-1754
Open location in Google Maps

Insurance Accepted

Aetna

  • Aetna Signature Administrators
  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Student Health

Affinity Health Plan

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs

Amida Care

  • Special Needs

Cigna

  • EPO
  • Great West (National)
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross/Blue Shield

  • EPO
  • HMO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Quality Health Management

  • Quality Health Management

RiverSpring

  • Special Needs

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • Oxford Freedom
  • Oxford HMO
  • Oxford Liberty
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

World Trade Center Health Plan

  • World Trade Center Health Plan

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • Columbia University College of Physicians and Surgeons
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Board Certifications

  • Infectious Disease

Research

Dr. Magdalena Sobieszczyk is the Harold Neu Professor of Infectious Diseases (in Medicine) and the Chief of Infectious Diseases at the Columbia University Irving Medical Center in New York. Dr. Sobieszczyk is a clinical virologist and the principal investigator of the NIH-funded Columbia Collaborative Clinical Trials Unit which has been advancing the science of HIV and emerging infections like SARS-CoV-2. Her research focuses on the development, testing, and implementation of biomedical interventions to prevent HIV and COVID-19 infections: specifically, vaccines, monoclonal antibodies, and pre-exposure prophylaxis (PrEP). She has led many large-scale NIH-funded international studies in these areas.

Since the start of the COVID-19 pandemic, she has established a prospective cohort to study epidemiology of COVID-19, cellular and antibody responses to primary infection and vaccination, and long-term effects of COVID-19 in diverse communities. She has led studies that focus on evaluating safety and efficacy of COVID-19 vaccines and other novel interventions to prevent and treat COVID-19. At the medical center, she oversaw the establishment of clinical management guidelines for treatment of COVID-19 and a multidisciplinary approach to the care of patients with long-COVID. She has been involved in educational and community outreach efforts to increase knowledge of COVID-19 vaccines and studies that address barriers to uptake. These efforts complement the ongoing clinical and translational research efforts that advance our understanding of this pathogen and are key elements of pandemic preparedness for other emerging or re-emerging pathogens.

Her HIV work also extends to testing interventions that address healthcare disparities and access to HIV care and prevention among women and minoritized MSM. This includes investigating gaps in the HIV prevention continuum and access to prevention services in the predominantly Latino and Black communities of northern Manhattan. The overarching aim of this body of research has been testing of interventions to support uptake, adherence, and persistence to PrEP and preparing for implementation of future biomedical interventions.

Research Interests

  • HIV prevention strategies, specifically clinical trials of preventive HIV vaccines

Selected Publications

  1. Sobieszczyk ME, Maaske J, Falsey AR, Sproule S, Robb ML, Frenck RW Jr, Tieu HV, Mayer KH, Corey L, Neuzil KM, Tong T, Brewinski Isaacs M, Janes H, Bansal H, Edwards LM, Green JA, Kelly EJ, Shoemaker K, Takas T, White T, Bhuyan P, Villafana T, Hirsch AI; AstraZeneca AZD1222 Clinical Study Group. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. J Clin Invest. 2022 Sep 15;132(18):e160565.
  2. Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L, Ho DD. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022 Aug;608(7923):603-608.
  3. Falsey AR**, Sobieszczyk ME**, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, Durbin A, Pickrell P, Daar ES, Bush L, Solis J, Carr QO, Oyedele T, Buchbinder S, Cowden J, Vargas SL, Guerreros Benavides A, Call R, Keefer MC, Kirkpatrick BD, Pullman J, Tong T, Brewinski Isaacs M, Benkeser D, Janes HE, Nason MC, Green JA, Kelly EJ, Maaske J, Mueller N, Shoemaker K, Takas T, Marshall RP, Pangalos MN, Villafana T, Gonzalez-Lopez A; AstraZeneca AZD1222 Clinical Study Group. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021 Dec 16;385(25):2348-2360. (** contributed equally)
  4. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021; 593, 130–135
  5. Zucker J, Gomez-Simmonds A, Purpura LJ, Shoucri S, LaSota E, Morley NE, Sovic BW, Castellon MA, Theodore DA, Bartram LL, Miko BA, Scherer ML, Meyers KA, Turner WC, Kelly M, Pavlicova M, Basaraba CN, Baldwin MR, Brodie D, Burkart KM, Bathon J, Uhlemann AC, Yin MT, Castor D, Sobieszczyk ME. Supervised Machine Learning Approach to Identify Early Predictors of Poor Outcome in Patients with COVID-19 Presenting to a Large Quaternary Care Hospital in New York City. J Clin Med. 2021 Aug
  6. Mehta M, Purpura LJ, McConville TH, Neidell MJ, Anderson MR, Bernstein EJ, Dietz DE, Laracy J, Gunaratne SH, Miller EH, Cheng J, Zucker J, Shah SS, Chaudhuri S, Gordillo CA, Patel SR, Guo TW, Karaaslan LE, Reshef R, Miko BA, Bathon JM, Pereira MR, Uhlemann AC, Yin MT, Sobieszczyk ME. What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak. PLoS One. 2021 Apr 8;16(4):e0249349.
  7. Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, Mgodi NM, decamp AC, Rudnicki E, Huang Y, Gonzales P, Cabello. R, Orrell C, Lama JR,  Laher. F, Lazarus EM, Sanchez. J, Frank. I, Hinojosa J, Sobieszczyk ME, Marshall KE, Mukwekwerere PG, Makhema J, Baden LR, Mullins JI, Williamson C, Hural J, McElrath JM, Bentley C, Takuva S, Gomez Lorenzo MM, Burns DN, Espy N,  Randhawa AK, Kochar N, Piwowar-Manning E, Donnell DJ, Sista N, Andrew P, Kublin JG, Gray G, Ledgerwood JE, Mascola JR, Cohen MS. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med 2021; 384:1003-1014
  8. Theodore DA, Greendyke WG, Miko B, Whittier S, Green DA, Shoucri S, Verna EC, Zucker J, Sobieszczyk ME, Aaron JG, Scully BE, Saiman L, Pereira M, Furuya EY. Cycle Thresholds Among Solid Organ Transplant Recipients Testing Positive for SARS-CoV-2. Transplantation. 2021 Jul 1;105(7):1445-1448
  9. Gulick RM, Sobieszczyk ME, Landry DW, Hollenberg AN. Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City. J Clin Invest. 2020 Sep 1;130(9):4522-4524.
  10. Geleris J,  Sun Y;  Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020; 382:2411-2418
  11. Mgbako O, Miller EH, Santoro AF, Remien RH, Shalev N, Olender S, Gordon P, Sobieszczyk ME. COVID-19, Telemedicine, and Patient Empowerment in HIV Care and Research. AIDS Behav. 2020 Jul;24(7):1990-199
  12. Laracy J, Zucker J, Castor D, McMahon DJ, Guo TW, Yan M, Shalev N, Scherer M, Gordon P, Sobieszczyk M, Yin MT. HIV-1 Infection Does Not Change Disease Course or Inflammatory Pattern of SARS-CoV-2-Infected Patients Presenting at a Large Urban Medical Center in New York City. Open Forum Infect Dis. 2021 Jan 28;8(2):ofab029.
  13. Shalev N, Scherer M, LaSota ED, Antoniou P, Yin MT, Zucker J, Sobieszczyk ME. Clinical Characteristics and Outcomes in People Living With HIV Hospitalized for COVID-19. Clin Infect Dis. 2020 Nov 19;71(16):2294-2297
  14. Yumori C,  Zucker J, Theodore D, Chang M, Carnevale C, Slowikowski J, LaSota E, Olender S, Gordon P, Cohall A, Sobieszczyk ME. Women Are Less Likely to Be Tested for HIV or Offered Preexposure Prophylaxis at the Time of Sexually Transmitted Infection Diagnosis. Sex Transm Dis. 2021 Jan;48(1):32-36.
  15. Zucker J, Carnevale C, Richards P, Slowikowski J, Borsa A, Gottlieb F, Vakkur I, Hyden C, Olender S, Cohall A, Gordon P, Sobieszczyk ME. Predictors of Disengagement in Care for Individuals Receiving Pre-Exposure Prophylaxis (PrEP). J Acquir Immune Defic Syndr. 2019 Apr 11
  16. Zucker J, Patterson B, Ellman T,  Slowikowski J, Olender S, Gordon P, Morrison E, Sobieszczyk ME. Missed Opportunities for Engagement in the Prevention Continuum in a Predominantly Black and Latino Community in New York City. AIDS Patient Care and STDs. AIDS Patient Care and STDs. AIDS Patient Care STDS. 2018 Nov;32(11):432-437
  17. Zucker J, Carnevale C, Rai AJ, Gordon P, Sobieszczyk ME. Positive or Not, that is the Question: HIV Testing for Individuals on Pre-Exposure Prophylaxis (PrEP). J Acquir Immune Defic Syndr. 2018 Feb 21.
  18. Sobieszczyk ME, Werner L, Mlisana K, Naicker N, Feinstein A, Gray CM, Masson L, Passmore JS, Williamson C, Karim QA, Abdool Karim SS, Garret NJ. Metabolic syndrome after HIV acquisition in South African women. J Acquir Immune Defic Syndr. 2016 Jul 6. [Epub ahead of print]
  19. Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton KE, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath MJ, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF.

20. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. 2015 Aug 14;349(6249):aab1253.

  1. Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer S, Sobieszczyk ME. Testing the waters: ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial. Clinical trials. Apr 7, 2015.
  2. Ellman TM, Hawkins K, Benitez J, Negron R, Chang S, Palmer S, Robertson V, Chiasson MA, Sobieszczyk ME. Representation of Latino and Black Men and Transgender women Screening and Enrolling into Preventive HIV Vaccine Trials in New York City. Vaccine. 2015;33(48):6809-15.
  3. Tang E., Sobieszczyk ME., Shu E., Gonzalez P., Sanchez J., Lama J. Provider Attitudes toward Oral Pre-Exposure Prophylaxis for HIV Prevention among High-Risk MSM in Lima, Peru. AIDS Research and Human Retroviruses 30(5):416-24.2014
  4. Ellman TM, Sexton ME, Warshafsky D, Sobieszczyk ME, Morrison E.  A Forgotten Population: Older Adults Newly-Diagnosed with HIV. AIDS Patient Care and STDs. Volume 28, Number 10, 2014
  5. Hammer S.M., Sobieszczyk ME, Janes H. et al. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. New England J of Medicine, 2013 10.1056/NEJMoa1310566.
  6. Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME. Translational Research Insights from Completed HIV Vaccine Efficacy Trials. Journal of AIDS 2013; (63) Supplement 2, July 1
  7. Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, and Hammer SM. In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. AIDS Research and Human Retroviruses 2013. ahead of print. doi:10.1089/aid.2012.0385